Works in Blood Cancer Journal, 2025, Vol 15, Issue 1
Results: 41
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01251-7
- By:
- Publication type:
- Article
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01248-2
- By:
- Publication type:
- Article
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortium.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01240-w
- By:
- Publication type:
- Article
Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01253-5
- By:
- Publication type:
- Article
Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01238-4
- By:
- Publication type:
- Article
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.
- Published in:
- 2025
- By:
- Publication type:
- Letter
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01235-7
- By:
- Publication type:
- Article
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01225-9
- By:
- Publication type:
- Article
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01222-y
- By:
- Publication type:
- Article
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01244-6
- By:
- Publication type:
- Article
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01225-9
- By:
- Publication type:
- Article
Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01231-x
- By:
- Publication type:
- Article
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01224-w
- By:
- Publication type:
- Article
Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01239-3
- By:
- Publication type:
- Article
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01238-4
- By:
- Publication type:
- Article
Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01229-5
- By:
- Publication type:
- Article
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-024-01207-3
- By:
- Publication type:
- Article
Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01214-y
- By:
- Publication type:
- Article
CALR<sup>ins5</sup>-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1<sup>Ser320Asn</sup> carrier.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01216-w
- By:
- Publication type:
- Article
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01213-z
- By:
- Publication type:
- Article
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and "real-world" data.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01211-1
- By:
- Publication type:
- Article
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-024-01208-2
- By:
- Publication type:
- Article
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-024-01205-5
- By:
- Publication type:
- Article
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01210-2
- By:
- Publication type:
- Article
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01209-9
- By:
- Publication type:
- Article
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-024-01198-1
- By:
- Publication type:
- Article
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01209-9
- By:
- Publication type:
- Article
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01236-6
- By:
- Publication type:
- Article
High WEE1 expression is independently linked to poor survival in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01230-y
- By:
- Publication type:
- Article
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01233-9
- By:
- Publication type:
- Article
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01232-w
- By:
- Publication type:
- Article
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01228-6
- By:
- Publication type:
- Article
Correction: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01227-7
- By:
- Publication type:
- Article
Defining 'Intention' in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01220-0
- By:
- Publication type:
- Article
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01212-0
- By:
- Publication type:
- Article